

# FORENSICS- ULTRA ESOTERIC NON ROUTINE DRUG TESTING

Isheetta Gupta

SRMS Institute Of Medical Sciences, Bareilly

## Abstract

They are easy to carry out, and one does not need to have much training to do them. As a result, they are useful in circumstances in which there may be a shortage of laboratory facilities. These may be carried out in the field by field technicians or police officers, need a small amount of reagents, are very affordable, and produce rapid findings that can be seen clearly with the naked eye. Medical examiners and coroners who are looking for extremely specialised forms of toxicological testing can get assistance from the CFSRE. Ultra-esoteric toxicological testing involves the investigation of very demanding chemicals or matrices which can be seldom identified or submitted, respectively.

**keywords:** *Forensics, ultra esoteric, drug*

## Introduction

Initial testing and evaluation of Color tests, which are also frequently referred to as chemical spot tests, give with one of the primary instruments for the presumptive identification of drugs and are one of the most common ways in which drugs are identified. These colour tests are particularly useful when applied to medications and residues found at crime scenes. To a lesser degree, they can also be used to biological fluids including the contents of the stomach, urine, and other bodily fluids. They are utilised in the process of assigning the unidentified to a certain category of compounds or in the process of removing categories or classes of compounds. These colour tests continue to be quite popular for a few different reasons. They are easy to carry out, and one does not need to have much training to do them. As a result, they are useful in circumstances in which there may be a shortage of laboratory facilities. These may be carried out in the field by field technicians or police officers, need a small amount of reagents, are very affordable, and produce rapid findings that can be seen clearly with the naked eye. Spraying or dipping colour tests, as opposed to using them just as location reagents for thin-layer chromatography, can be effective in many different situations. In comparison to immunoassays and chromatographic methods like gas chromatography and high performance liquid chromatography, colour tests can offer an indication of the chemical class in a significantly shorter amount of time.

The results of colour tests can only serve as an indicator of the existence of a drug or class of compounds; furthermore, the results of every test need to be validated by procedures that are more precise. This is of particular importance only in situations when the findings of tests might eventually lead to protective sentences. Testing are often conducted either in test-tubes made of transparent glass or on tiles made of white glazed porcelain (referred to as "spotting tiles"), both of which provide a consistent backdrop against which colours may be evaluated. At the same time that the sample being tested is being analysed, another sample that is known to be free of the chemical of interest should also be analysed. This allows for a comparison to be made between the colours generated by the sample and those generated by the reagent blank. Validation of all tests and test reagents, including their sensitivity and specificity, is an absolute need.

## **Ultra-Esoteric Toxicology**

Non-routine toxicological testing is one of the areas of expertise at the CFSRE. Postmortem analysis of insulin analogues and other very complicated targets are two examples. Moreover, the creation of niche analytical procedures for infrequently occurring medicines or toxins is another example. In typical laboratories, high-complexity targets are not commonly operational; nonetheless, large-molecule testing is essential for diagnosing the cause of death in unusual circumstances. Medical examiners and coroners who are looking for extremely specialised forms of toxicological testing can get assistance from the CFSRE.

## **Research**

The testing of ultra-esoteric toxicology involves the examination of extremely difficult chemicals or matrices, both of which can be seldom discovered or submitted, respectively. Due to the necessity of specialised instrumentation, non-routine equipment, novel or developing software, and/or complicated processes, analytical testing for these compounds is typically difficult to locate or is entirely unavailable. The research programme offered by CFSRE is one of a kind since it provides possibilities to create procedures that fall under this umbrella. These approaches will aid the forensic toxicology community.

## **Benefits**

- Traditional forensic toxicology laboratories seldom conduct ultra-esoteric toxicology testing, which means that these analyses may not be done, and the chemicals may not be reported.
- Ultra-specialized toxicological testing calls for the utilisation of specialised procedures and a high level of competence.
- The CFSRE is an industry leader in postmortem testing of insulin extracted from a wide variety of biological matrices, such as vitreous, blood, and tissues.
- The CFSRE established a quantitative approach for the detection of 2,4-dinitrophenol (DNP) and applied the method to the study of real casework specimens. The method was successful in determining whether or not the casework was legitimate.

## **Forensic Toxicology**

The effects and risks that are linked with the consumption of alcohol and drugs are the primary focus of the forensic toxicology research that is carried out at the CFSRE. Driving while under the influence of drugs, medical and legal investigations of deaths, and clinical simulations of overdoses are three primary areas of research. The study of the toxicity and chemistry of new psychoactive drugs takes up a significant amount of our research activities (NPS). Other study areas focus on analytical and interpretive issues connected with forensic toxicology.

## **Drug Impaired Driving**

Driving under the influence of drugs is becoming increasingly common in the United States, which raises serious concerns about public safety. Despite appeals for standardisation and improved standards, there is not a prescribed methodology to the analysis of cases from driving under the influence of drugs (DUID) investigations at this time. The CFSRE analyses epidemiological features of drugs in DUID cases in partnership with law enforcement and forensic laboratories. This monitoring can lead to the establishment of evidence-based public policy if the CFSRE is successful.

## **Medicolegal Death Investigation**

The number of people dying as a result of drug overdoses in the United States is steadily rising, particularly the number of deaths caused by synthetic opioids. To get a full picture of the circumstances surrounding a drug-related passing, it is often necessary for forensic toxicologists, medical examiners or coroners, and others who investigate deaths to work together. The Central Forensic Science Research Establishment (CFSRE) is primarily concerned with the development of assays for the detection and quantification of drugs in postmortem biological matrices, in addition to the interpretation of the findings of these tests.

## **Drug Facilitated Crimes**

When under the influence of drugs, an individual is more likely to break the law, which can lead to the commission of drug-facilitated crimes (DFC). Theft, sexual assault, extortion of money, and violence are just examples of crimes that can be committed. To identify the substance or substances that were used in the commission of a drug-facilitated sexual assault (DFSAs), extensive toxicological testing must be performed on the biological samples that were obtained. Sample matrix, assay sensitivity and scope, and toxicologist interpretation are some of the unique aspects and concerns that must be taken into account.

## **Forensic Significance of Drug Identification**

The use of drugs is no longer a threat; rather, it has developed into a widespread problem. The vast majority of cases that are brought to a forensic laboratory begin with the possibility that drugs were involved. To aid the investigating officer in determining whether a mortality was the result of an accident, a suicide, or a homicide, a toxicological analysis has to be carried out. A fatality might have been caused by any of these three things. Because the investigating officer frequently does not know whether or not any offence has been committed until the results of the toxicological analyses are available, it is essential to formulate the appropriate questions for him or her to ask in order to obtain answers that are accurate and useful. Basic tests are not, under any circumstances, intended to replace pharmacopoeial requirements; rather, they should be used as a quick and inexpensive method to substantiate the identity and potency of drugs and medicinal products, and possibly to detect low-quality counterfeit and other substandard products. It is important to keep this in mind. In the case that potentially harmful items are found, such products have to be examined to see whether or not they conform to the pharmacopoeial specifications.

## **Reasons To Use Clinical Drug Testing in Primary Care**

The phrase "drug testing" is often misunderstood since it gives the impression that the test can identify the presence of any and all substances. Drug tests, on the other hand, are only able to identify certain compounds or classes of substances, and they can only do so when the quantities of those substances exceed certain limits (cutoff levels). The word "drug screening," on the other hand, might be misleading because it is frequently used to refer to different kinds of drug testing. Nevertheless, in the context of forensic drug testing, the term "drug screening" most commonly refers to the use of immunoassay tests to differentiate specimens that test negative for a drug and/or metabolite from those that test positive for the drug and/or metabolite. The phrase "drug testing" will be used throughout the remainder of this TAP. Drug testing has the potential to be a useful clinical tool if it is applied correctly in the context of patient care. Pain management with opioid medications, office-based opioid treatment, primary care, psychiatry, and other clinical situations in which healthcare providers need to determine alcohol or other substance use in patients are examples of the types of clinical situations in

which clinical drug testing can be used. In addition, individuals who have been administered drugs that have the potential to become addicted are subjected to drug testing. Because individuals may not always accurately disclose their drug usage to medical experts (Chen, Fang, Shyu, and Lin, 2006), the self-reports of certain patients should be considered inaccurate. The findings of drug tests could give more accurate information than what the patient reports on their own. Although testing for drugs can be a helpful tool in clinical decision-making, it should not be the sole one available to clinicians. Drug testing, when combined with a patient's medical history, collateral information from a spouse or other family member (obtained with the patient's permission), questionnaires, biological markers, and a practitioner's clinical judgement, provides information that can help determine whether or not a patient is abusing drugs:

- Has the potential to influence therapeutic decisions on a patient's use of substances, which in turn influences other medical conditions.
- Has the potential to influence clinical decisions on pharmacotherapy, particularly those involving controlled drugs.
- Raise the overall level of safety associated with prescription pharmaceuticals by highlighting the possibility of adverse drug interactions or drug overdoses.
- Assists healthcare professionals in evaluating a patient's usage of opioids for the management of chronic pain or compliance with pharmacotherapy for opioid maintenance treatment for opioid use disorders.
- Assists the physician in evaluating the effectiveness of the treatment plan as well as the current level of care for the management of chronic pain and drug use disorders (SUDs).
- Protects patients from potentially life-threatening drug interactions during operations and other medical procedures.
- Assists in screening, evaluating, and diagnosing a substance use disorder, despite the fact that drug testing alone is not conclusive evidence of a substance use disorder.
- Identifies women who are pregnant or who want to get pregnant and who are using drugs or alcohol; this includes women who are pregnant or who want to become pregnant.
- Identifies at-risk neonates.
- Tracks continued sobriety in patients known to have a substance use disorder.
- Confirms, refutes, or provides further information on a patient's self-report or a family member's account of substance use.
- Identifies a recurrence to drug use

## **Drug**

**DRUG** A drug is any chemical that is used or suggested to be utilized to change or study physiological structures or pathological situations for the benefit of the receiver, as stated by the World Health Organization (WHO).

Eg: paracetamol, ciprofloxacin, sal-butamol, or it can be said that

A substance that, when ingested or put into the body of a person or animal, may have effects such as medical effects, intoxication effects, performance-enhancing benefits, or other effects, but that is not recognized to be a food or a food supplement is referred to as a drug. Depending on the drug control legislation, the government regulation, whether or not it is considered medical, or whether or not it is used, drugs are described differently in each of these categories. The term "drug" refers to "a chemical substance that is used in the treatment, cure, prevention, or diagnosis of disease or that is otherwise used to enhance physical or mental well-being." This

definition comes from the field of pharmacology. When treating chronic conditions, a physician may decide to prescribe medication for a specific amount of time or on an ongoing basis. Recreational drugs are chemical compounds that have an effect on the central nervous system (CNS). Some examples of recreational drugs are hallucinogens and opiates. Abuse of substances of this sort occurs because to the distinct positive impact they have on a person's awareness, perception, conduct, and personality. The first step in drug misuse is becoming dependent on and habituated to the substance. Drugs that are taken from outside the body are often differentiated from endogenously produced biochemicals by their exogenous origin. For instance, insulin is considered to be a hormone when it is produced by the pancreas within the body, but it is considered to be a medicine when it is injected into the body from the outside. Hormones play an important role in the regulation of blood sugar levels.

## Classification of Drugs

Different drugs can be organized under the following two categories according to the function that they serve in the user's life:

- Therapeutic Drugs
- Psychoactive Drugs

Despite the fact that both of these categories frequently intersect with one another. Because of their many applications and broad scope, psychotropic substances are categorized as their own separate class.

## Therapeutic Drugs

A substance that is either taken in order to treat or prevent the occurrence of a disease, or that is given to a patient in order to facilitate medical diagnosis, is referred to as a therapeutic medication. The therapeutic medications that are most often used may mostly be categorized as belonging to one of the following four groups:

**1) Analgesics and Antipyretics.** An analgesic is a specific category of drugs that are used to relieve pain. On the other hand, a medicine that is classified as an antipyretic is one that is used to bring down the temperature of the body. In this particular class of medications, the most typical uses are aspirin and paracetamol.

Aspirin, also known as acetylsalicylic acid, is a white crystalline powder with an acidic taste that is often used in homes to treat aches, pains, and other similar conditions. Because of the idiosyncrasies of this medicine, even quite low dosages might end up being lethal. However, the minimum amount required to cause death is approximately 5-10 grams.

These days, paracetamol, also known as acetaminophen, is often used in lieu of aspirin. Paracetamol is a metabolite of phenacetin. It has been determined that the lethal dose of 20 pills, each containing 500 milligrams, must be consumed between three to five days.

**2) Antihistaminics.** These are the medications that counteract the effects of the chemical histamine. These are frequently utilized in the treatment of allergic disorders in addition to other conditions such as the common cold. Promethazine hydrochloride (trade name: Phenergan), diphenhydramine (trade name: Benadryl),

chlorcyclizine (trade name: Histantin), antazoline (trade name: Antistine), and other medications are among the most prevalent formulations. A dosage of around one gram is lethal.

**3) Antidepressants.** These are the medications that are often prescribed to patients suffering from mental health conditions in order to alleviate their endogenous depression. These medicines first provide a sedative effect, and then, after about a week or more, they begin to have an antidepressant impact on the user.

Commonly used antidepressant drugs are: Imipramine, Amitriptyline, etc.

**4) Tranquilizers.** These are the kind of pharmaceuticals that may make a person feel calm all over without impairing their ability to think clearly or causing them to fall asleep. In order to alleviate the stress and worry felt by mental patients Tranquilizers like reserpine and chlorpromazine are beneficial.

## Development of Drug Testing

Drug testing that is conducted for therapeutic reasons is very different from drug testing programmes that are implemented in the workplace. On the other hand, clinical drug testing depends on the experience of the Federal Required Workplace Drug Testing, and it may be good to research workplace drug testing in order to have a better understanding of drug testing. The fact that the bulk of drug testing is conducted for objectives related to the job is one of the most important reasons why clinical practitioners should get familiar with federal mandatory workplace drug testing. Because of this, the majority of laboratories and many point-of-care tests (POCTs) utilise the cutoff concentrations that were established by the Required Guidelines for Federal Workplace Drug Testing Programs, which were detailed in the previous article. There are three categories of drug testing: (1) federally regulated for selected Federal employees (including military personnel and those in safety-sensitive positions); (2) federally regulated for non-Federal employees in safety-sensitive positions (i.e., airline and railroad personnel, commercial truckers, and school bus drivers); and (3) nonregulated for non-Federal employees.

The first category of drug testing applies to employees who are selected by the federal government and who are in safety-sensitive positions. The greatest segment of the population that is subjected to drug testing consists of commercial truck drivers, railroad workers, and airline staff. Both Federal workplace drug testing, which is always regulated, and non-Federal workplace drug testing, which may or may not be regulated, have the same purpose, which is to ensure the safety of the workplace by preventing the hiring of people who use illegal drugs and identifying employees who use illegal drugs. Federal workplace drug testing is always regulated. Non-Federal workplace drug testing may or may not be regulated.

## Conclusion

Drug testing is an essential component of clinical care and treatment for drug abuse when it is conducted with due diligence and thorough interpretation of the results. However, because test results can be deceiving if they are not interpreted in the appropriate clinical context, clinicians should always conduct a careful interview with adolescent patients to understand what testing is likely to show and then use testing to validate or refute their expectations. This is because test results can be deceiving. In light of the ease with which samples may be altered, service providers should also carefully reflect on the collection processes and sample validation procedures that they use in order to guarantee the highest possible level of precision.

## Reference

- [1] Adams, N. J., Plane, M. B., Fleming, M. F., Mundt, M. P., Saunders, L.A., & Stauffacher, E. A. (2001). Opioids and the treatment of chronic pain in a primary care sample. *Journal of Pain and Symptom Management*, 22(3), 791–796.
- [2] American Medical Association. (2006). *CPT 2006: Current procedural terminology professional edition*. Chicago: Author.
- [3] Barnes, A. J., De Martinis, B. S., Gorelick, D. A., Goodwin, R. S., Kolbrich, E. A., & Huestis, M. A. (2009). Disposition of MDMA and metabolites in human sweat following controlled MDMA administration. *Clinical Chemistry*, 55(3), 454–462.
- [4] Baselt, R. C. (Ed.). (2008). *Disposition of toxic drugs and chemicals in man* (8th ed.). Foster City, CA: Biomedical Publications.
- [5] Black, D., & Andreasen, N. (2011). *Introductory textbook of psychiatry* (5th edition). Washington, DC: American Psychiatric Publishing, Inc.
- [6] Bosker, W. M., & Huestis, M. A. (2009). Oral fluid testing for drugs of abuse. *Clinical Chemistry*, 55(11), 1910–1931.
- [7] Bosy, T., & Cole, K. (2000). Consumption and quantitation of delta-9-tetrahydrocannabinol in commercially available hemp seed oil products. *Journal of Analytical Toxicology*, 24(7), 562–566.
- [8] Boumba, V. A., Ziavrou, K. S., & Vougiouklakis, T. (2006). Hair as a biological indicator of drug use, drug abuse or chronic exposure to environmental toxicants. *International Journal of Toxicology*, 25(3), 143–163.
- [9] Center for Substance Abuse Treatment. (1997). *A guide to substance abuse services for primary care clinicians*. Treatment Improvement Protocol (TIP) Series 24. HHS Publication No. (SMA) 08-4075. Rockville, MD: Substance Abuse and Mental Health Services Administration.
- [10] Chawarski, M. C., Fiellin, D. A., O'Connor, P. G., Bernard, M., & Schottenfeld, R. S. (2007). Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. *Journal of Substance Abuse Treatment*, 33(4), 411–415.
- [11] Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P., et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *Journal of Pain*, 10(2), 113–130.
- [12] Cone, E. J. (1996). Mechanisms of drug incorporation into hair. *Therapeutic Drug Monitoring*, 18(4), 438–443.
- [13] Cone, E. J. (2006). Oral fluid testing: New technology enables drug testing without embarrassment. *Journal of the California Dental Association*, 34(4), 311–315.
- [14] Cone, E. J., & Huestis, M. A. (2007). Interpretation of oral fluid tests for drugs of abuse. *Annals of the New York Academy of Sciences*, 1098(51–103). doi:10.1196/annals.1384.037
- [15] Dasgupta, A. (2007). Effects of adulterants and selected ingested compounds on drugs-of-abuse testing in urine. *American Journal of Clinical Pathology*, 128(3), 491–503.
- [16] Fleming, M. F. (1995). Competencies for substance abuse training. In C. Sirica (Ed.), *Training about alcohol and substance abuse for all primary care physicians*. New York: Josiah Macy Jr., Foundation.
- [17] Huang, M. H., Wu, M. Y., Wu, C. H., Tsai, J. L., Lee, H. H., & Liu, R. H. (2007). Performance characteristics of ELISAs for monitoring ketamine exposure. *Clinica Chimica Acta*, 379(1–2), 59–65.
- [18] Huestis, M. A., Gustafson, R. A., Moolchan, E. T., Barnes, A., Bourland, J. A., Sweeney, S. A., et al. (2007). Cannabinoid concentrations in hair from documented cannabis users. *Forensic Science International*, 169(2–3), 129–136.

- [19] Jufer, R., Walsh, S., Cone, E., & Sampson-Cone, A. (2006). Effect of repeated cocaine administration on detection times. *Journal of Analytical Toxicology*, 30(7), 458–462.
- [20] Kacinko, S. L., Jones, H. E., Johnson, R. E., Choo, R. E., & Huestis, M. A. (2008). Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. *Clinical Pharmacology and Therapeutics*, 84(5), 604–612.